Abstract:Background Psoriasis arthritis is one of chronic, relapsing, inflammatory autoimmune disorders with skin lesions and joint damage. A therapeutic revolution of psoriatic arthritis (PsA) is still a considerable unmet need in the past decades. It has been well known that the imbalance of Th17 cells and regulatory T cells (Tregs) may be a pivotal cause of PsA. Correction of this dysfunction can be a potential therapy of PsA. Objectives In this study, we measured and compared both absolute numbers and proportions of CD4+CD17+ Th17 cells and CD4+CD25+Foxp3+ Treg cells in peripheral blood of PsA patients and healthy controls to explore the immunopathogenesis of PsA; on the other hand, the effects of low-dose recombinant human IL-2 (rhIL-2) on Th17 and Treg cells were investigated in patients with PsA. Methods Both absolute numbers and proportions of Treg and Th17 cells in peripheral blood, defined as the CD4+CD25+Foxp3+T or CD4+IL-17+ T cell populations, were examined by flow cytometry in 40 healthy controls and 77 patients with PsA, including 39 patients who had never received disease-modifying antirheumatic drugs (DMARDs) and 38 patients who were receiving or had received DMARDs. Among these patients, 20 patients consented at enrollment to receive rhIL-2 treatment. Before and after treatment (50WIU/d for 5 days, IH), Th17 and Treg cells in peripheral blood were analyzed by flow cytometry. Results The absolute count of Th17 cells in patients with PsA was very significantly higher than that of healthy controls (P<0.01), but the proportions of Th17 cell were not seen difference between PsA and healthy controls (P>0.05). In contrast with treated-PsA patients, the absolute count of Th17 cells was significant higher in untreated-PsA patients (P<0.05). After the course of rhIL-2 treatment, there was a significant increase in the absolute count of Treg cells (P<0.05), but no diference in the absolute count of Th17 cells, Th17/Treg was significantly lower and went back to nomal. Conclusions The results suggest that, not the proportion, but the decrease in the absolute count of Th17 cells, defined as the CD4+CD17+ populations, contributes to the pathogenesis of PsA. After the treatment of rhIL-2, there was a more significant increase in the absolute count of Treg cells than that of Th17, and consequently the balance of Th17/Treg was restored to normal, leading to the development of new therapies. References Karczewski J, Dobrowolska A, Rychlewskahańczewska A, et al. New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis[J]. Autoimmunity, 2016:1.DOI:10.3109/08916934.2016.1166214. Yoo I S, Lee J H, Song S T, et al. T-helper 17 cells: the driving force of psoriasis and psoriatic arthritis.[J]. International Journal of Rheumatic Diseases, 2012, 15(6):531–537. DOI:10.1111/j.1756–185X.2012.01813.x. Szodoray P, Nakken B, Barath S, et al. Altered Th17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders[J]. Human Immunology, 2013, 74(12):1510–8. DOI:10.1016/j.humimm.2013.08.003. Raychaudhuri S P. Role of IL-17 in psoriasis and psoriatic arthritis.[J]. Clinical Reviews in Allergy & Immunology, 2013, 44(2):183–193. DOI: 10.1007/s12016–012–8307–1. Disclosure of Interest None declared

The efficacy and safety of short-term and low-dose IL-2 combined with tocilizumab to treat rheumatoid arthritis

Efficacy and safety of humanized interleukin-6 receptor antibody in treatment of systemic juvenile idiopathic arthritis

SAT0213 Low Dose Il-2 Restores Decreased Absolute Number of Regulatory T Cells and Imbalance Between Th17 and Regulatory T Cells in Patients with Rheumatoid Arthritis

Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: A randomized controlled trial

AB0465 EFFICACY AND SAFETY OF LOW-DOSE IL-2 IN PATIENTS WITH RHEUMATOID ARTHRITIS

Usefulness of Tocilizumab for Treating Rheumatoid Arthritis with Myelodysplastic Syndrome

The Efficacy and Safety of Tocilizumab Combined with Disease-Modifying Anti-Rheumatoid Drugs in the Treatment of Active Rheumatoid Arthritis: a Multi-Center, Randomized, Double-Blinded, Placebocontrolled Trial

SAT0163 Absolute Number of Peripheral Cd4-Cd25+foxp3+t Cells Decreases and Restores after Low-Dose Interleukin-2 Treatment in Rheumatoid Arthritis

Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial

Low-dose IL-2 Therapy Limits the Reduction in Absolute Numbers of Circulating Regulatory T Cells in Rheumatoid Arthritis.

OP0028 Low Dose IL-2 Therapy Can Recovery TH17/TREG Cell Balance in Patients with Ankylosing Spondylitis

SAT0459 Low Dose IL-2 Restores Imbalance Between TH17 and Regulatory T Cells in Patients with Psoriatic Arthritis

Efficacy of tocilizumab on disease activity and psychological state in patients with refractory rheumatoid arthritis

AB0612 Efficacy of Low Dose and Short-Term IL-2 Treatment to Expand Endogenous Regulatory T Cells in Patients with Mixed Connective Tissue Disease

Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis.

OP0043 the Number of Circulating Regulatory T Cells is Reduced and Low-Dose Il-2 Selectively Stimulates Its Proliferation in Patients with Systemic Lupus Erythematosus

Efficacy, Safety and the Lymphocyte Subset Changes of Low-Dose IL-2 in Patients with Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis

THU0176 Efficiency and safety of rapamycin combined with low-dose IL-2 treatment compared with methotrexate in patients with rheumatoid arthritis

THU0412 Absolute reduction of peripheral cd4 + regulatory t cell subset of patients with systemic sclerosis and its restoration by short-term and low dose il-2 treatment

Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis

The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis